Triple-negative breast cancer trials in Hong Kong

4 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  Where

  Hong Kong

  Age

  18 years and over

  People

  1,000 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06841354 · EU 2024-516834-36-00
• Phase 3Taking people
  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  Where

  Jordan, Pokfulam, Shatin, Tuenmen

  Age

  18 years and over

  People

  2,400 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06966700 · EU 2024-520190-12-00
• Phase 3Taking people
  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  Where

  Hong Kong, Kowloon, Shatin

  Age

  18 years and over

  People

  1,530 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06393374 · EU 2023-504962-52-00
• Phase 3Taking people
  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  Where

  Hong Kong

  Age

  18 years and over

  People

  625 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06103864